A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
Recruiting · NCT07213960 · Registry updated 2026-09-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis | focal segmental glomerulosclerosis | Recruiting | Phase 2 / Phase 3 | 2026-09-02 | NCT07213960 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Apellis Pharmaceuticals, Inc. | 6 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Investigator Site 1 | Chicago | United States | 1 |
| Investigator Site 2 | New York | United States | 1 |